Systematic review and meta-analysis reports semaglutide improves cardiovascular outcomes, suggesting benefits for patients with risks.
Semaglutide effectively reduces the risk of MACE and modestly improves cardiovascular mortality rates and nonfatal myocardial infarction, without significantly affecting nonfatal stroke incidence and hospitalizations (for angina and heart failure). While it lowers the occurrence of serious adverse events, it also increases the likelihood of discontinuing treatment.
No takes yet. Share an insight, caveat, or question.
Sadraei et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: